MAIA Biotechnology, Inc. is a biopharmaceutical company focused on developing oncology drug candidates to improve and extend the lives of people with cancer. The company specializes in targeted therapy and immuno-oncology, with a primary focus on telomere-targeting agents for cancer treatment. Its flagship product is THIO, a first-in-class cancer telomere-targeting agent currently in clinical development for non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
- THIO (6-thio-dG) - A first-in-class cancer telomere-targeting agent in clinical development for treating NSCLC patients with telomerase-positive cancer cells. Telomerase is present in over 85% of cancers, making THIO a critical innovation in oncology.
- Next-Generation Telomere-Targeting Agents - A pipeline of 84 new molecules with the same mechanism of action as THIO, expected to follow THIO to the commercial stage within 4-5 years.
- Clinical Trials - Includes THIO-101 for NSCLC, THIO-102 for colorectal cancer (CRC), hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), and soft tissue tumors, and THIO-103 for NSCLC and SCLC.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Vlad Vitoc ExecutiveBoard | Chief Executive Officer | Vlad Vitoc is the Chief Executive Officer, Chairman of the Board, and President of MAIA Biotechnology, Inc., holding these roles since September 2018. He brings over 24 years of experience in the pharmaceutical and biotechnology industries, having led strategic initiatives and oncology pipeline developments. | View Report → | |
Jeffrey Himmelreich Executive | Head of Finance and Principal Financial and Accounting Officer | Jeffrey Himmelreich is an experienced financial executive who has served as Head of Finance and Principal Financial and Accounting Officer at MAIA Biotechnology since November 2023, and previously served as Director of Accounting and Financial Reporting from September 2023 to November 2023. | ||
Sergei M. Gryaznov Executive | Chief Scientific Officer | Sergei M. Gryaznov is the Chief Scientific Officer at MAIA Biotechnology, Inc. since December 2019. He is a recognized scientist in oncology and telomere research and previously served as Senior Director Head at Janssen Biopharma from May 2015 to October 2019. | ||
Cristian Luput Board | Director | Founder and CEO of Optimus Realty Inc; Board Member of several charitable organizations | Cristian Luput serves as a Director at MAIA Biotechnology, leveraging his extensive management and entrepreneurial experience. He is also the founder and CEO of Optimus Realty Inc since 2005, along with serving as a board member for several charitable organizations. | |
Jean-Manassé Theagéne Board | Director | CEO of 360Medlink; Strategic Advisor | Jean-Manassé Théagène is a Director at MAIA Biotechnology, Inc., elected to the Board on March 17, 2023 with a term lasting until the 2025 annual meeting. He is also the founder and CEO of 360Medlink since November 2010, bringing over 20 years of life sciences experience. | |
Louie Ngar Yee Board | Director | Louie Ngar Yee serves as a Director on the Board of Directors of MAIA Biotechnology, Inc. since April 2020. She previously served as the Group Chief Operating Officer of Group Internal Audit at HSBC Group from January 2017 to March 2020. | ||
Ramiro Guerrero Board | Director | Founder and CEO of IMPERIO, Inc. | Ramiro Guerrero serves as a Director at MAIA Biotechnology since March 24, 2023. He is also the Founder and CEO of IMPERIO, Inc. since March 2015, with extensive experience in real estate investment, brokerage, and venture capital. | |
Stan V. Smith Board | Director | President, Smith Economics Group, Ltd.; Adjunct Professor at University of Chicago; Adjunct Professor at DePaul University College of Law | Stan V. Smith has served as a Director at MAIA Biotechnology, Inc. since at least March 21, 2024 and is nominated for re-election as a Class III director for a term expiring at the 2026 annual meeting. He brings extensive expertise in economics, financing, and litigation economics to the board. | |
Steven Chaouki Board | Director | President, U.S. Markets & Consumer Interactive at TransUnion | Steven Chaouki is currently serving as Director at MAIA Biotechnology, Inc., as evidenced by filings dated April 19, 2023 and April 21, 2023. He has extensive management experience, including serving as President, U.S. Markets & Consumer Interactive at TransUnion since 2008. |
Research analysts covering MAIA Biotechnology.
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Current competitors in the non-small lung cancer indication include this company, which is part of a competitive landscape involving both large and small companies developing products for this indication. Key product features such as efficacy, safety, convenience, and pricing will affect the ability to compete effectively. | |
This company is identified as a competitor in the non-small lung cancer indication and is also the manufacturer of cemiplimab, an immune checkpoint inhibitor used in combination with THIO in clinical trials. | |
This company is listed among the current competitors in the non-small lung cancer indication, highlighting the competitive nature of the biotechnology and pharmaceutical industries. | |
Roche | This company is noted as a competitor in the non-small lung cancer indication, emphasizing the significant competition in developing therapies for this condition. |
Recent press releases and 8-K filings for MAIA.
- MAIA Biotechnology, Inc. announced a private placement involving the sale of 603,769 shares of common stock at a purchase price of $1.22 per share.
- Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $1.52 per share.
- The private placement is expected to generate approximately $736,600 in gross proceeds.
- The company intends to use the net proceeds from the offering to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
- The closing of the private placement is anticipated on or about October 15, 2025.
- MAIA Biotechnology, Inc. has entered into definitive agreements for a private placement of 603,769 shares of common stock at a purchase price of $1.22 per share.
- Each share of common stock is offered with a warrant to purchase one share at an exercise price of $1.52 per share, exercisable six months after issuance for a term of three years.
- The offering is expected to generate approximately $736,600 in gross proceeds.
- The net proceeds will be used to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
- MAIA Biotechnology, Inc. announced on October 7, 2025, the launch of a new digital asset treasury strategy focused on top-tier cryptocurrency assets.
- The company's Board of Directors has authorized holding up to 90% of its liquid assets in various cryptocurrencies.
- The initial cryptocurrencies approved for purchase and sale are Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC).
- This strategy aims to diversify the investment portfolio and create shareholder value for shareholders.
- MAIA Biotechnology, Inc. announced on October 7, 2025, the launch of a new digital asset treasury strategy.
- The company's Board of Directors has authorized holdings of up to 90% of its liquid assets in cryptocurrencies.
- Corporate officers are authorized to purchase and sell Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC) initially.
- The strategy aims to diversify the investment portfolio with leading crypto tokens, minimize risk, and create shareholder value.
- MAIA Biotechnology, Inc. announced a private placement on September 29, 2025, expecting to raise approximately $2.25 million in gross proceeds.
- The private placement involves the sale of 1,733,766 shares of common stock at a purchase price of $1.30 per share, with each share accompanied by a warrant to purchase an additional share at an exercise price of $1.57.
- The net proceeds from this offering are intended to fund Step 1 of Part C of the Phase II trial THIO -101 and for working capital.
- Concurrently, the company amended existing common stock purchase warrants, originally issued on February 24, 2025, for 1,396,667 shares, reducing their exercise price from $1.87 per share to $1.30 per share.
- MAIA Biotechnology, Inc. announced on September 24, 2025, that it was awarded a $2.3 million grant by the National Institutes of Health (NIH).
- This grant is for the expansion of its THIO-101 Phase 2 clinical trial, evaluating ateganosine as a third-line treatment for advanced non-small cell lung cancer (NSCLC).
- The $2.3 million NIH grant will be distributed over three years from 2025-2027 to support the enrollment of U.S. patients.
- As of June 30, 2025, the THIO-101 trial showed a median overall survival of 17.8 months for 22 patients, compared to 5 to 6 months for standard-of-care chemotherapy treatments.
- MAIA Biotechnology, Inc. reported positive efficacy data from its THIO-101 Phase 2 clinical trial for ateganosine in patients with advanced non-small cell lung cancer (NSCLC).
- As of June 30, 2025, the estimated median progression-free survival (PFS) in third-line treatment was 5.6 months, which is more than double the standard of care PFS of 2.5 months.
- The estimated median overall survival (OS) was 17.8 months.
- The THIO-101 Phase 2 expansion trial began enrolling patients in July 2025.
- MAIA Biotechnology announced positive efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine in patients with advanced non-small cell lung cancer (NSCLC).
- As of June 30, 2025, the estimated median progression-free survival (PFS) in third-line treatment was 5.6 months, which is more than double the standard of care PFS of 2.5 months, and the estimated median overall survival (OS) was 17.8 months.
- The data also indicated potential for extended dosing, with two patients completing 33 cycles of therapy, and a Phase 2 expansion trial began enrolling patients in July 2025 to further validate efficacy.
- CEO Vlad Vitoc outlines the 2025 clinical milestones in the Shareholder Letter, emphasizing MAIA’s lead candidate THIO (ateganosine) as the sole clinical-stage telomere-targeting anticancer agent.
- The letter details a Phase 2 trial expansion for THIO-101 with potential accelerated approval filing and a Phase 3 trial for THIO-104 set to begin mid-2025 with regulatory actions anticipated in 2026.
- MAIA Biotechnology, Inc. filed a Form 8-K on March 28, 2025, reporting the release of efficacy data from its Phase 2 THIO-101 clinical trial in combination with the immune checkpoint inhibitor cemiplimab for advanced NSCLC.
- The efficacy data was presented as a poster at the European Lung Cancer Congress 2025 and is now available on the company’s website as Exhibit 99.1.